Astrazeneca plc
AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Pays a 1.73% dividend yield.
Current Price
$184.74
-1.40%GoodMoat Value
$228.37
23.6% undervaluedAstrazeneca plc (AZN) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Astrazeneca plc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $60.44B. Gross profit (TTM) is $49.37B. EBITDA is $20.46B. Earnings per share (EPS) is $6.54. The P/E ratio is 27.58. Market capitalization is $286.51B.
Free cash flow (FCF) is $11.78B. FCF growth rate is 34.08%. EPS growth CAGR is 40.40%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Astrazeneca plc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
